By Cecilia Butini

Novartis AG said Friday that it will co-develop cancer drug tislelizumab with China-based pharmaceutical company BeiGene as part of an in-licensing agreement.

The Swiss pharma giant said it will initiate additional clinical trials to study the drug's efficacy on different types of cancer, as tislelizumab is now only approved in China for patients with non-small cell lung cancer, classical Hodgkin's lymphoma and metastatic urothelial carcinoma.

The agreement--the financial details of which weren't disclosed--is valid for North America, Europe and Japan, Novartis said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

February 26, 2021 07:33 ET (12:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novartis Charts.